Your Article Summary
See Latest ArticlesSafety and Outcomes of Open-Label Deferasirox Iron Chelation Therapy for Mucormycosis
Antimicrobial Agents and Chemotherapy, 06/29/09
Spellberg B et al. - Deferasirox was administered for an average of 14 days at 5 to 20 mg/kg of body weight/day. Deferasirox treatment was not associated with changes in renal or liver function, complete blood count, or transplant immunosuppressive levels. Thus, deferasirox appears safe as an adjunctive therapy for mucormycosis.
Related Articles
A Successful Combined Endovascular and Surgical Treatment of A Cranial Base Mucormycosis With An Associated Internal Carotid Artery Pseudoaneurysm
Neurosurgery, 10/07/09
Relevance Score: 88%
Rhino-Orbital-Cerebral Mucormycosis: A Lethal Complication of Body Dysmorphic Disorder
Ophthalmic Plastic and Reconstructive Surgery, 10/06/09
Relevance Score: 83%
Ulcerative leg nodules in a transplant recipient
Cleveland Clinic Journal of Medicine, 10/16/09
Relevance Score: 82%
Today in Antimicrobials...keeping you current
Receive free subspecialty "5-minute updates" via email
Temporal Reduction of HIV Type 1 Viral Load in Breast Milk by Single-Dose Nevirapine during Prevention of MTCT
AIDS Research and Human Retroviruses, 12/18/09
Update on the efficacy, effectiveness and safety of artemether–lumefantrine combination therapy for treatment of uncomplicated malaria
Therapeutics and Clinical Risk Management, 12/18/09
Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action
Clinical Pharmacokinetics, 12/18/09